Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline

Fahad Al-Hameed, a Hasan M Al-Dorzi, b Abdulkarim Al Momen, c Farjah Algahtani, c Hazzaa Al Zahrani, d Khalid Al Saleh, e Mohammed Al Sheef, f Tarek Owaidah, d Waleed Alhazzani, g,h Ignacio Neumann, g,h Wojtek Wiercioch, h Jan Brozek, g,h Holger Schünemann, g,h Elie A. Akl h,i

From the aCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Intensive Care Department, King Abdulaziz Medical City, NGHA, Jeddah, Saudi Arabia; bCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Intensive Care Department, King Abdulaziz Medical City, NGHA, Riyadh, Saudi Arabia; cDepartment of Hematology, King Saud University, Riyadh, Saudi Arabia; dDepartment of Hematology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; eDepartment of Hematology, King Saud University, Riyadh, Saudi Arabia; fDepartment of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia; gDepartment of Medicine, McMaster University, Hamilton, Canada; hDepartment of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada; iDepartment of Internal Medicine, American University of Beirut, Lebanon

Correspondence: Elie A. Akl, MD, MPH, PhD · Department of Internal Medicine, American University of Beirut PO Box: 11-0236 Riad-El-Solh Street Beirut 1107 2020 Lebanon · T: + 961 1 374374 · ea32@aub.edu

Ann Saudi Med 2015; 35(2): 95-106
DOI: 10.5144/0256-4947.2015.95

BACKGROUND AND OBJECTIVES: Venous thromboembolism (VTE) is commonly encountered in the daily clinical practice. Cancer is an important VTE risk factor. Proper thromboprophylaxis is key to prevent VTE in patients with cancer, and proper treatment is essential to reduce VTE complications and adverse events associated with the therapy.

DESIGN AND SETTINGS: As a result of an initiative of the Ministry of Health of Saudi Arabia, an expert panel led by the Saudi Association for Venous Thrombo-Embolism (a subsidiary of the Saudi Thoracic Society) and the Saudi Scientific Hematology Society with the methodological support of the McMaster University working group produced this clinical practice guideline to assist health care providers in evidence-based clinical decision-making for VTE prophylaxis and treatment in patients with cancer.

METHODS: Six questions related to thromboprophylaxis and antithrombotic therapy were identified and the corresponding recommendations were made following the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.

RESULTS:

Question 1. Should heparin versus no heparin be used in outpatients with cancer who have no other therapeutic or prophylactic indication for anticoagulation?

Recommendation: For outpatients with cancer, the Saudi Expert Panel suggests against routine thromboprophylaxis with heparin (weak recommendation; moderate quality evidence).

Question 2. Should oral anticoagulation versus no oral anticoagulation be used in outpatients with cancer who have no other therapeutic or prophylactic indication for anticoagulation?

Recommendation: For outpatients with cancer, the Saudi Expert Panel recommends against thromboprophylaxis with oral anticoagulation (strong recommendation; moderate quality evidence).

Question 3. Should parenteral anticoagulation versus no anticoagulation be used in patients with cancer and central venous catheters?

Recommendation: For outpatients with cancer and central venous catheters, the Saudi Expert Panel suggests thromboprophylaxis with parenteral anticoagulation (weak recommendation; moderate quality evidence).

Question 4. Should oral anticoagulation versus no anticoagulation be used in patients with cancer and central venous catheters?

Recommendation: For outpatients with cancer and central venous catheters, the Saudi Expert Panel suggests against thromboprophylaxis with oral anticoagulation (weak recommendation; low quality evidence).

Question 5. Should low-molecular-weight heparin versus unfractionated heparin be used in patients with cancer...
Venous thromboembolism (VTE), comprising deep venous thrombosis (DVT) and pulmonary embolism, is a relatively common disease with cancer being one of its important risk factors. In fact, patients with cancer have an approximately sevenfold increased risk of VTE compared with those without cancer. The malignant cells themselves induce a hypercoagulable state, and the cancer type, stage, and histological grade contribute to the thrombosis risk. Additionally, factors related to cancer management, such as surgery, chemotherapy, radiotherapy, hormonal therapy, hospitalization, and indwelling central venous catheters, increase further the VTE risk. Prophylaxis and treatment of VTE can be challenging, as patients with cancer have a higher risk of both VTE recurrence and bleeding complications. Hence, the proper selection of VTE prophylaxis and treatment modalities and their use in the right setting is crucial.

According to the Saudi Cancer Registry, cancer incidence in Saudi Arabia in 2010 was 13,706 patients. Based on data from the Middle East, it is estimated that the 5-year cancer prevalence is 0.28% of the population, which corresponds to approximately 80,000 patients in Saudi Arabia. Clinical data from Saudi Arabia on VTE in cancer patients are scarce. A retrospective study of 701 patients with solid tumors or lymphoma who were treated at a tertiary-care center in Riyadh from 2004 to 2009 found that VTE was diagnosed in 6.7% with 79% of VTE patients having an advanced cancer stage.

Aiming at guiding health care providers working in Saudi Arabia in evidence-based VTE management, the Saudi Ministry of Health (MoH) arranged for this clinical practice guideline and obtained the methodological support of the McMaster University guidelines group. In this document, we report the recommendations of the Saudi expert panel for VTE prophylaxis and treatment in cancer patients.

**METHODS**

In 2013, the Saudi MoH embarked on a program of rigorous adaptation and de novo development of clinical practice guidelines to provide guidance for clinicians to ensure high quality of care and reduce variability in clinical practice across Saudi Arabia. Hence, the Saudi MoH, through the Saudi Center for Evidence-Based Healthcare, partnered with the McMaster University guidelines group to provide methodological support and contacted the Saudi Scientific Hematology Society and the Saudi Association for VTE to nominate a group of clinicians to serve as an expert panel for guideline development on VTE prophylaxis and treatment in cancer patients. In the following, we briefly describe the methodology used to develop recommendations and grade the quality of the supporting evidence. The details of the methodology are available in a separate publication.

The overall process

The Saudi Arabia guideline panel selected the topic of this guideline and all related questions using a formal prioritization process. For all selected questions, the McMaster University working group identified the related systematic reviews of randomized controlled trials published in the Cochrane Library, and then searched for trials that were subsequently published in Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE until November 2013. The reviews were then updated by incorporating the new eligible trials. These updates were later published in the Cochrane Library. The group also conducted systematic searches for information that was required to develop full guidelines for Saudi Arabia, including searches for information about patients’ values and preferences and cost (resource use) specific to the Saudi context.

Next, the McMaster guideline leader developed for each question a summary of findings table and an evi-
dence-to-recommendation table and shared them with the panel members. The guideline panel was invited to provide additional information, particularly when published evidence was lacking. The final step consisted of an in-person meeting of the guideline panel in Riyadh on December 3, 2013, to develop the final recommendations. We used the evidence-to-recommendation tables to follow the structured consensus process and transparently document all decisions made during the meeting. The guideline panel formulated all recommendations during this meeting. Potential conflicts of interests of all panel members were managed according to the World Health Organization rules.17

The selected questions

The following is a list of the clinical questions selected by the Saudi Arabia guideline panel and addressed in this guideline. For details on the process by which the questions were selected, please refer to the separate methodology publication.10

1. Should heparin versus no heparin be used in outpatients with cancer who have no other therapeutic or prophylactic indication for anticoagulation?

2. Should oral anticoagulation versus no oral anticoagulation be used in outpatients with cancer who have no other therapeutic or prophylactic indication for anticoagulation?

3. Should parenteral anticoagulation versus no anticoagulation be used in patients with cancer and central venous catheters?

4. Should oral anticoagulation versus no anticoagulation be used in patients with cancer and central venous catheters?

5. Should low-molecular-weight heparin (LMWH) versus unfractionated heparin (UFH) be used in patients with cancer being initiated on treatment for venous thromboembolism?

6. Should heparin versus oral anticoagulation be used in patients with cancer requiring a long-term treatment of VTE?

Grading the quality of evidence

The panel assessed the quality of evidence using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.18 Quality of evidence was classified as “high,” “moderate,” “low,” or “very low” based on decisions about methodological characteristics of the available evidence for a specific health care problem. The definition of each category is as follows:19

* High: We are very confident that the true effect lies close to that of the estimate of the effect.

* Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

* Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

* Very Low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Grading the strength of recommendations

The GRADE Working Group defines the strength of recommendation as the extent to which we can be confident that desirable effects of an intervention outweigh undesirable effects.20 According to the GRADE approach, the strength of a recommendation is either strong or conditional (weak) and has explicit implications (Table 1).20 Understanding the interpretation of these 2 grades—either strong or conditional—of the strength of recommendations is essential for sagacious clinical decision-making.

The panel provided recommendations to cover the following 2 major topics: (1) Thromboprophylaxis in patients with cancer (Questions 1-4) and (2) Antithrombotic therapy in patients with cancer (Questions 5-6). The recommendations were made taking into consideration the available evidence, resource used, and the Saudi context.

RESULTS

The evidence for this guideline was based on 5 systematic reviews and meta-analysis,21-25 which included 51 eligible trials. The inclusion and exclusion criteria are detailed in the reviews.21-25 The updated search found 6 trials that were included in the updated meta-analyses. The full guideline with details of published report grading and recommendation process is available at: http://www.moh.gov.sa/depts/Proofs/Pages/Guidelines.aspx.

I. Thromboprophylaxis in patients with cancer

Question 1: Should heparin versus no heparin be used in outpatients with cancer who have no other therapeutic or prophylactic indication for anticoagulation?

The summary of evidence is based on a Cochrane systematic review by Akl et al.21 The updated published report search identified 3 additional studies that were included in the meta-analyses.26-28 Subgroup analyses by the type or stage of cancer were either not feasible or inconclusive. The summary of findings is reported in Table 2.21,26-28
Benefits of the option: The meta-analysis of 13 studies (7266 participants) found the moderate quality evidence for reduction in mortality (RR 0.95; 95% CI 0.89 to 1.00; absolute effect: 23 fewer per 1000 over 1 year). The meta-analysis had some but no serious heterogeneity across studies (I² = 15%). The meta-analysis of 12 studies (6998 participants) found the high quality evidence for reduction in VTE (RR 0.65; 95% CI 0.43 to 0.74; absolute effect: 23 fewer per 1000 over 1 year).

Harms of the option: The meta-analysis of 14 studies (7539 participants) found the moderate quality evidence of increase in major bleeding (RR 1.14; 95% CI 0.80 to 1.63; absolute effect: 2 more per 1000). The meta-analysis of 12 studies (7041 participants) found the moderate quality evidence of increase in minor bleeding (RR 1.32; 95% CI 1.03 to 1.70; absolute effect: 9 more per 1000).

Values and preferences: The panel’s judgment was that the typical patient would be against daily injections for duration of several months. Patients would view a potential reduction in mortality and symptomatic VTE favorably.

Resource use: The panel estimated the daily cost of an LMWH to be low. For example, the daily cost of enoxaparin was estimated at SR 20 per injection, a small unit cost. Applying this to the population level for a period of 6 months results in estimated costs of SR 36 million per 10000 cancer patients. Considering that a certain number of patients would not do self-injection (maybe as high as 50% of patients), they would have to go to a clinic or have nurse home visits.

Other considerations: The panel judgment was that it would be hard for policymakers to accept the intervention due to the cost and given this is a prophylaxis intervention.

Recommendation 1:
For outpatients with cancer, the Saudi Expert Panel suggests against routine thromboprophylaxis with...

Table 1. Interpretation of strong and conditional (weak) recommendations.

| Implications | Strong recommendation | Conditional (weak) recommendation |
|--------------|-----------------------|------------------------------------|
| For patients | Most individuals in this situation would want the recommended course of action, and only a small proportion would not. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences. | The majority of individuals in this situation would want the suggested course of action, but many would not. Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful helping individuals making decisions consistent with their values and preferences. |
| For clinicians | Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. | |
| For policy makers | The recommendation can be adapted as policy in most situations | Policy making will require substantial debate and involvement of various stakeholders. |

Table 2. Summary of findings: Heparin versus no heparin be used in patients with cancer who have no other therapeutic or prophylactic indication for anticoagulation.

| Patient or population: Patients with cancer who have no other therapeutic or prophylactic indication for anticoagulation | Interventions: LMWH Comparison: No LMWH |
|-------------------------------------------------|------------------------------------------|
| **Outcomes** | **Illustrative comparative risks** (95% CI) | **Relative effect** (95% CI) | **No. of participants (studies)** | **Quality of the evidence (GRADE)** |
|-----------------------------|-----------------------------|-----------------------------|-------------------------------|---------------------------------|
| Mortality at 12 mo | No LMWH: 459 per 1000 (409–459) | LMWH: 436 per 1000 | RR 0.95 (0.89–1) | 7266 (13 studies) | Moderate |
| Follow-up: 12 mo | No LMWH: 51 per 1000 (22–38) | LMWH: 29 per 1000 | RR 0.56 (0.43–0.74) | 6998 (12 studies) | High |
| Symptomatic VTE | No LMWH: 16 per 1000 (13–26) | LMWH: 18 per 1000 | RR 1.14 (0.8–1.63) | 7539 (14 studies) | Moderate |
| Major bleeding | No LMWH: 28 per 1000 (25–44) | LMWH: 31 per 1000 | RR 1.1 (0.89–1.55) | 7286 (13 studies) | High |

CI, Confidence interval; LMWH, low molecular weight heparin; RR, risk ratio; VTE, venous thromboembolism; GRADE, Grading of Recommendations, Assessment, Development and Evaluation.

*The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
heparin. (weak recommendation; moderate quality evidence)

Remarks:
* Use a validated tool (e.g., the Khorana risk assessment score) to risk stratify patients, as those at a higher risk for VTE are more likely to benefit
* This recommendation does not apply to patients who would otherwise have an indication for prophylaxis. Examples include: immobility, long-distance travel, highly thrombogenic drugs (e.g., thalidomide, lenalidomide, hormonal therapy, angiogenesis inhibitors), and high-risk cancer surgery patients.
* See separate recommendation for oral anticoagulation

Subgroup considerations: Although there is evidence for potential benefit in patients with small cell lung cancer, the evidence is of lower quality, so the recommendation applies to all types of cancers.

Question 2: Should oral anticoagulation versus no oral anticoagulation be used in outpatients with cancer who have no other therapeutic or prophylactic indication for anticoagulation?

The summary of evidence (Table 3) is based on a Cochrane systematic review by Akl et al. The updated published report search identified 1 additional phase II trial comparing apixaban to placebo. The trial included patients with cancer receiving chemotherapy and who were at an increased risk for thrombosis. Including the study in the meta-analyses did not substantively affect the results.

Benefits of the option: The meta-analysis of 5 studies (1604 participants) found moderate quality evidence of no effect on mortality (RR 0.94; 95% CI 0.87 to 1.03; absolute effect: 39 fewer per 1000 over 1 year). One study (315 participants) found the moderate quality evidence for reduction in VTE (RR 0.15; 95% CI 0.02 to 1.2; absolute effect: 25 fewer per 1000 over 1 year).

Harms of the option: The meta-analysis of 4 studies (1282 participants) found moderate quality evidence of increase in major bleeding (RR 4.24; 95% CI 1.85 to 9.68; absolute effect: 23 more per 1000). The meta-analysis of 3 studies (851 participants) found moderate quality evidence of increase in minor bleeding (RR 3.34; 95% CI 1.66 to 6.74; absolute effect: 63 more per 1000).

Values and preferences: The panel thought that the typical patient would find oral anticoagulation burdensome due to the frequent testing and monitoring, diet and medication restrictions, stoppage for procedures,..

**Table 3.** Summary of findings: Oral anticoagulation versus no oral anticoagulation be used in outpatients with cancer who have no other therapeutic or prophylactic indication for anticoagulation.

| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No. of participants | Quality of the evidence (GRADE) |
|----------|----------------------------------------|--------------------------|---------------------|------------------------------|
|          | Assumed risk                           | Corresponding risk       | (95% CI)            | (studies)                    |                             |
| Death    | Moderate                               | RR 0.94 (0.87–1.03)      | 1604 (5 studies)    | Moderate                     |                             |
| Follow-up: median 1 y | 649 per 1000 (565–668)               |                          |                     |                              |
| Symptomatic VTE | Moderate                           | RR 0.15 (0.02–1.2)      | 315 (1 study)       | Moderate                     |                             |
| Follow-up: 1 y    | 29 per 1000 (1–35)                   |                          |                     |                              |
| Major bleeding | Moderate                             | RR 4.24 (1.85–9.68)     | 1282 (4 studies)    | Moderate                     |                             |
| Follow-up: median 1 y | 7 per 1000 (13–68)               |                          |                     |                              |
| Minor bleeding | Moderate                             | RR 3.34 (1.66–6.74)     | 851 (3 studies)      | Moderate                     |                             |
| Follow-up: 1 y    | 27 per 1000 (45–182)                 |                          |                     |                              |

CI, Confidence interval; INR, international normalized ratio; RR, risk ratio; VTE, venous thromboembolism; GRADE, Grading of Recommendations, Assessment, Development and Evaluation.

*All studies used warfarin at a dose to increase prothrombin time 1.5 to 2 times (4 studies) or to keep INR between 1.3 and 1.9.

*The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
etc. Patients would view a potential reduction in mortality and symptomatic VTE favorably. **Resource use:** The panel estimated the unit cost to be low. However, visits for monitoring and lab testing would require significant resources. **Other considerations:** While the panel thought the intervention would be feasible, they judged it as probably not acceptable because of the lack of effectiveness (no effect on mortality) and cost-effectiveness.

**Recommendation 2:**
For outpatients with cancer, the Saudi Expert Panel recommends against thromboprophylaxis with oral anticoagulation. (strong recommendation; moderate quality evidence). **Key consideration:**
* This recommendation does not apply to patients who would otherwise have an indication for prophylaxis. Examples include: immobility, long-distance travel, highly thrombogenic drugs (e.g., thalidomide, lenalidomide, hormonal therapy, angiogenesis inhibitors).
* See separate recommendation for heparin anticoagulation.

**Table 4a.** Summary of findings: Parenteral anticoagulation versus no parenteral anticoagulation be used in cancer patients with central venous catheters.

| Outcomes       | Illustrative comparative risks a (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) |
|----------------|------------------------------------------|--------------------------|-----------------------------|--------------------------------|
| **Death**      | 64 per 1000 (35–83)                      | RR 0.85 (0.55–1.31)      | 1474 (6 studies)            | Moderate                       |
| **Symptomatic DVT** | 80 per 1000 (28–68)                  | RR 0.54 (0.35–0.85)      | 1455 (7 studies)            | High                           |
| **Major bleeding** | 5 per 1000 (1–26)                      | RR 0.68 (0.1–4.78)       | 891 (4 studies)             | Moderate                       |
| **Infection**  | 71 per 1000 (35–120)                    | RR 0.91 (0.49–1.88)      | 626 (3 studies)             | Moderate                       |
| **Thrombocytopenia** | 156 per 1000 (125–210)                  | RR 1.04 (0.8–1.34)       | 1118 (4 studies)            | Moderate                       |

**Table 4b.** Summary of findings: Parenteral anticoagulation versus oral anticoagulation be used in cancer patients with central venous catheters.

| Outcomes       | Illustrative comparative risks a (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) |
|----------------|------------------------------------------|--------------------------|-----------------------------|--------------------------------|
| **Death**      | 87 per 1000 (56–168)                     | RR 1.11 (0.84–1.93)      | 623 (3 studies)             | Low                            |
| **Symptomatic DVT** | 43 per 1000 (33–137)                  | RR 1.55 (0.76–3.15)      | 560 (3 studies)             | Low                            |
| **Major bleeding** | 0 per 1000 (0–0)                        | RR 3.1 (0.13–73.14)      | 343 (2 studies)             | Low                            |
| **Thrombocytopenia** | 202 per 1000 (245–492)                  | RR 1.71 (1.21–2.43)      | 339 (2 studies)             | Moderate                       |
Question 3: Should parenteral anticoagulation versus no anticoagulation be used in patients with cancer and central venous catheters?

The summary of evidence (Tables 4a & b) is based on a systematic review by Akl et al.23 The updated published report search identified 1 new trial that randomized patients with planned chemotherapy for cancer to no anticoagulant prophylaxis, LMWH, or warfarin 1 mg/d.31

Benefits of the option: The meta-analysis of 6 studies (1474 participants) found moderate quality evidence that did not rule out either an increase or a decrease in mortality (RR 0.85; 95% CI 0.55 to 1.31; absolute effect: 10 fewer per 1000 over 1 year).23 The meta-analysis of 7 studies (1455 participants) found the high quality evidence for reduction in VTE (RR 0.54; 95% CI 0.35 to 0.85; absolute effect: 37 fewer per 1000 over 1 year).23

Harms of the option: The meta-analysis of 4 studies (891 participants) found moderate quality evidence that did not rule out either an increase or a decrease in major bleeding (RR 0.68; 95% CI 0.1 to 4.78; absolute effect: 2 fewer per 1000).23

Values and preferences: The panel’s judgment was that the typical patient would be against daily injections for duration of several months. Patients would view a potential reduction in mortality and symptomatic VTE favorably.

Resource use: The panel judged the costs to be acceptable when anticoagulation is for a relatively short time period (e.g., 3 months).

Other considerations: The panel judged the intervention to be acceptable given it is a relatively short time period. It was also judged as feasible given patients would be coming back anyway for catheter care.

Recommendation 3:
For outpatients with cancer and central venous catheters, the Saudi Expert Panel suggests thromboprophylaxis with parenteral anticoagulation. (weak recommendation; moderate quality evidence).

Remarks:
* Use a validated tool (e.g., the Khorana risk assessment score29) to risk stratify patients, as those at a higher risk for VTE are more likely to benefit.
* This recommendation does not apply to patients, who would otherwise have an indication for prophylaxis. Examples include: immobility, long-distance travel, highly thrombogenic drugs (e.g., thalidomide, lenalidomide, hormonal therapy, angiogenesis inhibitors).
* See separate recommendation for oral anticoagulation.

Question 4: Should oral anticoagulation versus no anticoagulation be used in patients with cancer and central venous catheters?

The summary of evidence (Table 5) is based on a systematic review by Akl et al.23 The updated published report search identified 1 new trial that randomized patients with planned chemotherapy for cancer to no anticoagulant prophylaxis, LMWH, or warfarin 1 mg/d.31

Benefits of the option: The meta-analysis of 3 studies (1371 participants) found low quality evidence that did not rule out either an increase or a decrease in mortality (RR 0.97; 95% CI 0.82 to 1.15; absolute effect: 8 fewer per 1000 over 1 year).23 The meta-analysis of 5 studies (1513 participants) found the moderate quality evi-

### Table 5. Summary of findings, oral anticoagulation versus no oral anticoagulation be used in cancer patients with central venous catheters.

| Outcomes       | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) |
|----------------|-----------------------------------------|--------------------------|--------------------------------|---------------------------------|
| Death          | 260 per 1000                            | RR 0.97 (0.82–1.15)      | 1371 (3 studies)                | Low                             |
| Symptomatic DVT| 109 per 1000                            | RR 0.51 (0.29–0.89)      | 1513 (5 studies)                | Moderate                        |
| Major bleeding | 2 per 1000                              | RR 0.83 (0.68–0.96)      | 1093 (2 studies)                | Low                             |

*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Evidence for reduction in VTE (RR 0.51; 95% CI 0.29 to 0.89; absolute effect: 53 fewer per 1000 over 1 year).\textsuperscript{23}

**Harms of the option:** The meta-analysis of 2 studies (1093 participants) found low quality evidence that did not rule out either an increase or a decrease in major bleeding (RR 6.93; 95% CI 0.86 to 56.08; absolute effect: 11 more per 1000).\textsuperscript{23}

**Values and preferences:** The panel's judgment was that the typical patient would find oral anticoagulation burdensome due to the frequent testing and monitoring, diet and medication restrictions, stoppage for procedures, etc. Patients would view a potential reduction in mortality and symptomatic VTE favorably.

**Resource use:** The panel estimated the unit cost to be low. However, visits for monitoring and lab testing would require significant resources.

**Other considerations:** The panel judged the intervention to be acceptable given it is relatively short period. It was also judged as feasible given patients would be coming back anyway for catheter care.

**Recommendation 4:**
For outpatients with cancer and central venous catheters, the Saudi Expert Panel suggests against thromboprophylaxis with oral anticoagulation (weak recommendation; low quality evidence).

**Remarks:**
- Use a validated tool (e.g., the Khorana risk assessment score\textsuperscript{29}) to risk stratify patients, as those at a higher risk for VTE are more likely to benefit
- This recommendation does not apply to patients who would otherwise have an indication for prophylaxis. Examples include: immobility, long-distance travel, highly thrombogenic drugs (e.g., thalidomide, lenalidomide, hormonal therapy, angiogenesis inhibitors).
- Option could be offered to patients interested in thromboprophylaxis but averse to using injections (with LMWH).
- See separate recommendation for parenteral anticoagulation.

**II. Antithrombotic therapy in patients with cancer**

**Question 5:** Should LMWH versus UFH be used in patients with cancer being initiated on treatment for VTE?

The summary of evidence (Table 6) is based on a systematic review by Akl et al.\textsuperscript{24} The updated published report search did not identify any new studies.

**Benefits of the option:** The meta-analysis of 11 studies (801 participants) found the low quality evidence for reduction in mortality (RR 0.71; 95% CI 0.52 to 0.98; absolute effect: 55 fewer per 1000 over 3 months).\textsuperscript{24} The meta-analysis of 20 studies (6910 participants) found very low quality evidence suggesting a reduction in major bleeding (RR 0.67; 95% CI 0.45 to 1; absolute effect: 5 fewer per 1000 over 3 months).\textsuperscript{24}

**Harms of the option:** The meta-analysis of 3 studies (371 participants) found low quality evidence that did not rule out either an increase or a decrease in VTE (RR 0.71; 95% CI 0.29 to 2.08; absolute effect: 21 fewer per 1000 over 3 months).\textsuperscript{24}

**Values and preferences:** The panel judged that pa-

---

**Table 6. Summary of Findings: low molecular weight heparin compared to unfractionated heparin for the initial treatment of venous thromboembolism in patients with cancer.**

| Outcomes\textsuperscript{b} | Patient or population: patients with the initial treatment of venous thromboembolism in patients with cancer | Settings: Inpatient or outpatient Intervention: LMWH Comparison: UFH | Illustrative comparative risks\textsuperscript{a} (95% CI) Assumed risk | Corresponding risk | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) |
|-----------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------|---------------------|-----------------------|-----------------------------|-------------------------------|-----------------------------|
| Death at 3 months Follow-up: median 3 months | Death at 3 months Follow-up: median 3 months | Death at 3 months Follow-up: median 3 months | Death at 3 months Follow-up: median 3 months | Death at 3 months Follow-up: median 3 months | Death at 3 months Follow-up: median 3 months | Death at 3 months Follow-up: median 3 months | Death at 3 months Follow-up: median 3 months |
| Assumed risk | 189 per 1000 | 134 per 1000 (98 to 186) | RR 0.71 (0.52 to 0.98) | 801 (11 studies) | Low |
| Corresponding risk | 96 per 1000 | 75 per 1000 (28 to 200) | RR 0.78 (0.29 to 2.08) | 371 (3 studies) | Low |

\textsuperscript{a}The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

\textsuperscript{b}Data on major bleeding, post-phlebitic syndrome and thrombocytopenia were not reported. There is indirect evidence that both LMWH and UFH increase the risk of major bleeding compared with no anticoagulation.
patients’ preferences with relation to intravenous versus subcutaneous injections might vary, but the majority would value being discharged early.

Resource use: We did not identify any studies directly related to initial parenteral anticoagulation, so the panel relied on indirect evidence related to home treatment/early discharge of DVT. As stated earlier, health economic evaluations in both KSA and non-KSA settings conclude that home treatment of DVT is cost-saving.

Other considerations: The panel judged both interventions to be feasible and acceptable.

Recommendation 5:
In patients with cancer being initiated on treatment for venous thromboembolism, the Saudi Expert Panel suggests LMWH over intravenous UFH (weak recommendation; very low quality evidence).

Question 6: Should heparin versus oral anticoagulation be used in patients with cancer requiring long-term treatment of venous thromboembolism?

The summary of evidence is based on a Cochrane systematic review by Akl et al. The updated published reports search identified a new trial comparing Idraparinux to standard therapy in the treatment of DVT in cancer patients. Including the study in the meta-analysis did not substantially affect the results for mortality, VTE, or major bleeding. Table 7 describes the summary of findings.

Benefits of the option: The meta-analysis of 7 studies found moderate quality evidence that did not rule out a reduction in mortality with LMWH compared with oral anticoagulation (RR 0.96; 95% CI 0.81 to 1.13; absolute effect: 7 fewer per 1000 over 6 months). The meta-analysis of 8 studies found the moderate quality evidence for reduction in VTE with LMWH compared with oral anticoagulation (RR 0.62; 95% CI 0.46 to 0.84). The absolute effect varied by baseline risks associated with the stage of cancer; 30 fewer per 1000 over 6 months for patients with non-metastatic cancer and 76 fewer per 1000 over 6 months for patients with metastatic cancer. One study provided the low quality evidence for reduction in post-thrombotic syndrome with LMWH compared with oral anticoagulation (RR 0.85; 95% CI 0.77 to 0.94; absolute effect: 30 fewer per 1000 over 2 years).

Harms of the option: The meta-analysis of 8 studies found moderate quality evidence that did not rule out either an increase or a decrease in major bleeding (RR 0.81; 95% CI 0.55 to 1.2).

The absolute effect varied by baseline risks associated with the stage of cancer; 4 fewer per 1000 over 6 months for patients with non-metastatic cancer and 15 fewer per 1000 over 6 months for patients with metastatic cancer.

Values and preferences: The panel’s judgment was that patients might assign different values to the burden of warfarin versus LMWH. They typically assigned a high value to avoiding post-thrombotic syndrome.

Resource use: The panel’s judgment was that LMWH is more expensive than warfarin. Warfarin requires monitoring, testing, and frequent visits to the clinic.

Monitoring and evaluation: The Saudi Panel recommended close monitoring for vitamin K antagonist (VKA) therapy and monitoring of renal function and platelet count for LMWH therapy.

Other considerations: The panel judged LMWH to be both feasible and acceptable given its current use in practice.

Recommendation 6:
In patients with metastatic cancer requiring long-term treatment of VTE, the Saudi Expert Panel recommends LMWH over VKA. (strong recommendation; moderate quality evidence).

In patients with non-metastatic cancer requiring long-term treatment of venous thromboembolism, the Saudi Expert Panel suggests LMWH over VKA. (weak recommendation; moderate quality evidence)

Remarks:
* Patients who are apprehensive about injections may prefer VKA over LMWH.
* Patients who choose VKA will require closer monitoring.

DISCUSSION
This clinical practice guideline provides guidance on VTE prophylaxis and treatment in cancer patients. It is a part of the larger initiative of the Saudi MoH aiming at reducing variability in clinical practice across Saudi Arabia. The target audience includes primary care physicians and specialists in Emergency Medicine, Internal Medicine, and Hematology/Oncology. Other health care professionals, public health officers, and policy makers may also benefit from it. This guideline is not intended to provide a standard of care. It provides clinicians and their patients with the basis for rational decisions. Clinicians, patients, third-party payers, institutional review committees, other stakeholders, and courts should never view the recommendations in this guideline as dictates. No guideline can take into account all of the unique features of individual clinical circum-

Ann Saudi Med 2015 March-April www.annsaudimed.net
stances. The remarks accompanying each recommendation are integral parts and serve to facilitate its accurate interpretation. They should never be omitted when quoting or translating recommendations from this guideline.

This guideline did not cover all the scenarios of VTE prophylaxis and treatment in patients with cancer. The questions were selected based on a formal prioritization process. The recommendations in this guideline shared similarities with those of other societies and panels. Similar to the first recommendation, the American Society of Clinical Oncology does not recommend routine anticoagulant prophylaxis of ambulatory cancer patients except for patients on thalidomide or lenalidomide.56 The American Society of Clinical Oncology and an international consensus working group recommended initiation of VTE treatment with LMWH as in the fifth recommendation of this guideline.57,58 This guideline suggested against routine VTE prophylaxis in cancer patients with central venous catheters similar to the 9th edition of the Antithrombotic Therapy and Prevention of Thrombosis.59 However, this guideline did not address VTE prophylaxis for patients undergoing major cancer surgery. The American Society of Clinical Oncology recommended that such patients should start prophylaxis before surgery, continuing it for at least 7 to 10 days and considering the extension of

Table 7. Summary of findings: Heparin versus oral anticoagulation in patients with cancer requiring long-term treatment of venous thromboembolism.

| Outcomes                        | Patient or population: Patients with long term treatment of patients with VTE | Settings: Outpatient Intervention: LMWH Comparison: VKA | Illustrative comparative risks\(^a\) (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) |
|---------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------|--------------------------|-----------------------------|------------------------------|
| Death                           | Follow-up, median 6 mo                                                        |                                                       | 164 per 1000 (133–185)                      | RR 0.96 (0.81–1.13)      | 2496 (7 studies)            | Moderate                     |
|                                 | Low\(^b\)                                                                     |                                                       |                                             |                          |                             |                              |
|                                 | 30 per 1000 (14–25)                                                           |                                                       |                                             |                          |                             |                              |
| Recurrent VTE                   | Follow-up: median 6 mo                                                        |                                                       | 19 per 1000 (14–25)                         | RR 0.62 (0.46–0.84)      | 2727 (8 studies)            | Moderate                     |
|                                 | Moderate\(^b\)                                                                |                                                       |                                             |                          |                             |                              |
|                                 | 80 per 1000 (37–67)                                                           |                                                       |                                             |                          |                             |                              |
|                                 | High\(^b\)                                                                    |                                                       |                                             |                          |                             |                              |
|                                 | 124 per 1000 (92–168)                                                         |                                                       |                                             |                          |                             |                              |
| Major bleeding                  | Follow-up: median 6 mo                                                        |                                                       | 16 per 1000 (11–24)                         | RR 0.81 (0.55–1.2)       | 2727 (8 studies)            | Moderate                     |
|                                 | Low\(^b\)                                                                     |                                                       |                                             |                          |                             |                              |
|                                 | 80 per 1000 (44–96)                                                           |                                                       |                                             |                          |                             |                              |
| Post-phlebitic syndrome         | Self-reported leg symptoms and signs                                           | Follow-up: median 2 y                                 | 170 per 1000 (154–188)                      | RR 0.85 (0.77–0.94)      | 100 (1 study)               | Low                          |

CI, Confidence interval; LMWH, low molecular weight heparin; RR, risk ratio; VKA, vitamin K antagonist; VTE, venous thromboembolism; UFH, unfractionated heparin; GRADE, Grading of Recommendations, Assessment, Development and Evaluation.

\(^a\)The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

\(^b\)Low risk of recurrent VTE corresponds to patients without cancer; intermediate risk of recurrent VTE corresponds to patients with local or recently resected cancer; and high risk of recurrent VTE corresponds to patients with locally advanced or distant metastatic cancer.

\(^c\)Low risk of bleeding corresponds to the absence of any risk factor for bleeding (i.e., age >75 y; cancer; metastatic disease; chronic renal or hepatic failure; platelet count <80,000; antiplatelet therapy; history of bleeding without a reversible cause).

\(^d\)High risk of bleeding corresponds to the presence of at least 1 risk factor for bleeding (i.e., age >75 y; cancer; metastatic disease; chronic renal or hepatic failure; platelet count < 800,000; antiplatelet therapy; history of bleeding without a reversible cause).
prophylaxis for up to 4 weeks in high-risk patients.67 The 9th edition of the Antithrombotic Therapy and Prevention of Thrombosis recommends postoperative prophylaxis with LMWH for 4 weeks for patients at a high risk for VTE undergoing abdominal or pelvic surgery for cancer.68 This guideline also did not address extended anticoagulant therapy for patients with VTE and active cancer, which was recommended in the 9th edition of the Antithrombotic Therapy and Prevention of Thrombosis.69

The evidence used in the making of this guideline was frequently of low to moderate quality.21-25 Evidence coming from Saudi Arabia was also scarce. The Saudi Expert Panel suggested local research on the values and preferences of the Saudi population, including those who have cancer, regarding VTE treatment with the various modalities and the potential side effects from such treatments. The Panel advocated the performance of studies that identify which types and stages of cancer were more likely to benefit from thromboprophylaxis and those that evaluate the economic aspect of the different VTE treatment strategies in cancer patients. This guideline is on VTE prophylaxis and treatment in patients with cancer. In conclusion, the Saudi Expert Panel suggests against routine thromboprophylaxis with heparin and recommends against it with oral anticoagulants for outpatients with cancer. The panel suggests parenteral but not oral anticoagulant thromboprophylaxis in those who have central venous catheters. Additionally, the panel suggests LMWH over intravenous UFH for the initial VTE treatment and recommends LMWH over VKA for the long-term VTE treatment.

Acknowledgments
The authors would like to thank Dr. Mohammed Zamakhshary, Dr. Zulfa Alrayess, Dr. Yaer Adi, and the members of the Saudi Center for Evidence Based Healthcare (EBHC), MoH, Saudi Arabia, for their unlimited support.

REFERENCES
1. Goldhaber SZ, Bounnameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379(9818):1635-46.
2. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Jama 2005;293(9):715-22.
3. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35(1-2):103-10.
4. Konigsbrugge D, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res 2014;133 Suppl 2:S39-43.
5. Dutia M, White RH, Wun T. Risk assessment models for cancer-associated venous thromboembolism. Cancer 2012;118(14):3488-76.
6. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011;139(1):69-79.
7. Al-Eid HSD, Manuel A. Cancer Incidence Report Saudi Arabia 2010 Riyadh2014. Available from: www.chs.gov.sa.
8. Bray F, Ren JS, Massyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132(3):1132-40.
9. Alem A, Al Dabi AR, Alsateh K, Alghaffan F, Alsaleh E, Ibqal Z, et al. Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia. Asian Pac J Cancer Prev 2012;13(4):1311-5. Epub 2012/07/18. PubMed PMID: 22799324.
10. McMaster University Guideline Working Group. Methodology for the Development of the Ministry of Health of Saudi Arabia and McMaster University Clinical Practice Guidelines. 2014.
11. Akl EA, Kahale LA, Ballout RA, Barba M, Yusuo VC, van Doormaal FF, et al. Parenteral anti-coagulation in ambulatory patients with cancer. Cochrane Database Syst Rev. 2014;12:CD006652.
12. Akl EA, Kahale L, Terrentino I, Neumann I, Yo-suico VE, Barba M, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2014;7:CD006466.
13. Akl EA, Kahale L, Terrentino I, Neumann I, Yusico VE, Barba M, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2014;6:CD006466.
14. Akl EA, Ramly EP, Kahale LA, Yusico VE, Barba M, Sperati F, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev. 2014;10:CD006468.
15. Akl EA, Kahale L, Neumann I, Barba M, Sperati F, Terrentino I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;8:CD006469.
16. Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrentino I, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;7:CD006650.
17. World Health Organization. WHO Handbook for Guideline Development: World Health Organization; 2012 [cited 2014 February 7]. Available from: http://apps.who.int/iris/bitstre am:10665/124778/1/WHOCHOEP2013.1-eng.pdf.
18. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64(4):383-94.
19. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64(4):401-6.
20. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66(7):719-25.
21. Akl EA, Gunuku S, Barba M, Yusico VC, van Doormaal FF, Kuipers S, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. The Cochrane database of systematic reviews. 2011(4):CD006652.
22. Akl EA, Vaisireddi SR, Gunuku S, Yusico VE, Barba M, Terrentino I, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. The Cochrane database of systematic reviews. 2011(6):CD006466.
23. Akl EA, Vaisireddi SR, Gunuku S, Yusico VE, Barba M, Sperati F, et al. Anticoagulation for patients with cancer and central venous catheters. The Cochrane database of systematic reviews. 2011(4):CD006468.
24. Akl EA, Vaisireddi SR, Gunuku S, Barba M, Sperati F, Terrentino I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. The Cochrane database of systematic reviews. 2011(5):CD006650. doi: 10.1002/14651858.CD006469.pub5. PubMed PMID: 21678380.
25. Akl EA, Labedi N, Barba M, Terrentino I, Sperati F, Muti M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. The Cochrane database of systematic reviews. 2011(6):CD006650.
106 pancreatic cancer. Eur J Cancer 2012;48(9):1283-92.
28. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol: official journal of the ASCO 2011;29(15):2071-6.
29. Khorana AA. Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw 2011;9(1):789-97.
30. Levine MN, Gu C, Liebman HA, Escalante CP, Solyomo S, Deitchman D, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10(5):807-14.
31. Lavas-Denes S, Lacroix P, Mabouan A, Preux PM, Genet D, Venat-Bouvet L, et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol 2013;72(1):65-73.
32. Saighi A, Hosny G. Impact of an out-patient based strategy for the management of acute deep venous thrombosis in Saudi Arabia. Eur J Intern Med 2013;24:1170.
33. Alghantani F, Aseri ZA, Alaidab A, Aleem A. Hospital versus home treatment of deep vein thrombosis in a tertiary care hospital in Saudi Arabia: Are we ready? SJF: the official publication of the Saudi Pharmaceutical Society. 2013;22(1):165-8.
34. Backman K, Carlsson P, Kentson M, Hansen S, Engquist L, Hallert C. Deep venous thrombosis in Saudi Arabia. Eur J Echocardiogr 2013:22(1):67.
35. Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-Based Clinical Practice guidelines. Chest. 2012;141(2 Suppl):e227S-77S.
36. Huse D, Colome E, Bonell A, et al. A randomised open-label trial comparing long-term subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep vein thrombosis. J Vasc Surg 1996;20:521-7.
37. Venge F, Escriba A, Maluenda MP, Lopez RM, Margarei I, Lezana A, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep vein thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84(4):559-64.
38. Khorana AA, Khorana OA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-505. Epub 2007/10/31. doi: 10.1200/JCO.2007.14.1283. PubMed PMID: 17968019.
39. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AF, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 2015;33(6):654-6.
40. van den Belt AG, Bossuyt PM, Prins MH, Gal- lus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep vein thrombosis—an economic evaluation. TASM AN Study Group. Thromb Haemost 1998;79(2):259-63.
41. van Doornmaal FF, Cohen AT, Davidson BL, De- cousus H, Gallus AS, Gent M, et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost 2010;104(1):18-91.
42. Deitcher SR, Kessler CM, Marli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12(4):389-96. Epub 2006/09/27. doi: 12/4/389 [pii] 10.1177/1076029606239962. PubMed PMID: 17000884.
43. Hull RD, Pinoe GF, Brant RF, Mah AF, Burke N, Dear R, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007;120(1):72-82.
44. Hull RD, Pinoe GF, Brant R, Lian J, Cook R, Solyomo S, et al. Home therapy of deep vein thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009;122(1):762-9 e3.
45. Lee AF, Levine MN, Baker RI, Bowden C, Kak- kar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-53.
46. Lopaciuck S, Bielska-Falda H, Noszczyk W, Lopaciuck S, Bielska-Falda H, Noszczyk W, Filipecki S, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26-31.
47. Lopez-Beret P, Orga A, Fontcuberta J, Doblas M, Martinez A, Lozano G, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep vein thrombosis. J Vasc Surg 2001;33(1):77-80.
48. Meyer G, Marjanovic Z, Valcic J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archiv Int MedAUTHOR: Please check the journal abbreviation for correctness. ] 2002;162(15):1729-35.
49. Romera A, Cairilos MA, Vila-Coll R, Marti X, Colome E, Bonell A, et al. A randomised open-label trial comparing long-term subcutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009;37(3):349-56.
50. Hull RD, Pinoe GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal vein thrombosis treatment. J Vasc Surg 2009;49(2 Suppl):S94-S.
51. Quintavalla R, Poli T, et al. Low molecular weight heparin versus warfarin the prevention of recur- sion after deep vein thrombosis. Thromb Haemost 1994;72(2):191-7.
52. Das SK, Cohen AT, Edmondson RA, Mellissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial. World J Surg 1996;20:521-7.
53. Gonzalez-Fajardo JA, Areba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep ve- nue thrombosis. J Vasc Surg 1999;30(2):283-92.
54. Veiga F, Escriba A, Maluenda MP, Lopez RM, Margarei I, Lezana A, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep vein thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84(4):559-64.